LCTX | Lineage Cell Therapeutics, Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	0.4811 - 0.4990
52 Week Range	0.4700 - 1.5600
Beta	1.34
Implied Volatility	282.50%
IV Rank	37.55%
Day's Volume	1,337,933
Average Volume	1,813,413
Shares Outstanding	228,356,000
Market Cap	112,328,316
Sector	Healthcare
Industry	Biotechnology
IPO Date	1992-03-05

Valuation
Profitability
Growth
Health
P/E Ratio	-5.47
Forward P/E Ratio	N/A
EPS	-0.09
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	68
Country	USA
Website	LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LCTX's peers: ICCC, MAIA, ARMP, FREQ, PRTG, AGE, CVKD, ONTTF, REPL, NVCT, LYRA, KRON, GOSS, NLTX, NUVB, OVID, NXTC, CNTB, SPRO, BOLT, CHRS, GRCL

*Chart delayed

Analyzing fundamentals for LCTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see LCTX Fundamentals page.

Watching at LCTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on LCTX Technicals page.